» Articles » PMID: 21574207

Methods of the Pharmacological Imaging of the Cannabinoid System (PhICS) Study: Towards Understanding the Role of the Brain Endocannabinoid System in Human Cognition

Overview
Specialty Psychiatry
Date 2011 May 17
PMID 21574207
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Various lines of (pre)clinical research indicate that cannabinoid agents carry the potential for therapeutic application to reduce symptoms in several psychiatric disorders. However, direct testing of the involvement of cannabinoid brain systems in psychiatric syndromes is essential for further development. In the Pharmacological Imaging of the Cannabinoid System (PhICS) study, the involvement of the endocannabinoid system in cognitive brain function is assessed by comparing acute effects of the cannabinoid agonist Δ9-tetrahydrocannabinol (THC) on brain function between healthy controls and groups of psychiatric patients showing cognitive dysfunction. This article describes the objectives and methods of the PhICS study and presents preliminary results of the administration procedure on subjective and neurophysiological parameters. Core elements in the methodology of PhICS are the administration method (THC is administered by inhalation using a vaporizing device) and a comprehensive use of pharmacological magnetic resonance imaging (phMRI) combining several types of MRI scans including functional MRI (fMRI), Arterial Spin Labeling (ASL) to measure brain perfusion, and resting-state fMRI. Additional methods like neuropsychological testing further specify the exact role of the endocannabinoid system in regulating cognition. Preliminary results presented in this paper indicate robust behavioral and subjective effects of THC. In addition, fMRI paradigms demonstrate activation of expected networks of brain regions in the cognitive domains of interest. The presented administration and assessment protocol provides a basis for further research on the involvement of the endocannabionoid systems in behavior and in psychopathology, which in turn may lead to development of therapeutic opportunities of cannabinoid ligands.

Citing Articles

Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study.

Pollak T, De Simoni S, Barimani B, Zelaya F, Stone J, Mehta M Psychopharmacology (Berl). 2015; 232(24):4515-24.

PMID: 26438425 DOI: 10.1007/s00213-015-4078-8.


Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.

Hindocha C, Freeman T, Schafer G, Gardener C, Das R, Morgan C Eur Neuropsychopharmacol. 2014; 25(3):325-34.

PMID: 25534187 PMC: 4398332. DOI: 10.1016/j.euroneuro.2014.11.014.


A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation.

Solowij N, Broyd S, van Hell H, Hazekamp A BMC Pharmacol Toxicol. 2014; 15:58.

PMID: 25319497 PMC: 4274767. DOI: 10.1186/2050-6511-15-58.


Reduction in cerebral perfusion after heroin administration: a resting state arterial spin labeling study.

Denier N, Gerber H, Vogel M, Klarhofer M, Riecher-Rossler A, Wiesbeck G PLoS One. 2013; 8(9):e71461.

PMID: 24039715 PMC: 3769358. DOI: 10.1371/journal.pone.0071461.


Default mode network in the effects of Δ9-Tetrahydrocannabinol (THC) on human executive function.

Bossong M, Jansma J, van Hell H, Jager G, Kahn R, Ramsey N PLoS One. 2013; 8(7):e70074.

PMID: 23936144 PMC: 3729458. DOI: 10.1371/journal.pone.0070074.


References
1.
van Osch M, Teeuwisse W, van Walderveen M, Hendrikse J, Kies D, van Buchem M . Can arterial spin labeling detect white matter perfusion signal?. Magn Reson Med. 2009; 62(1):165-73. DOI: 10.1002/mrm.22002. View

2.
Vink M, Kahn R, Raemaekers M, van den Heuvel M, Boersma M, Ramsey N . Function of striatum beyond inhibition and execution of motor responses. Hum Brain Mapp. 2005; 25(3):336-44. PMC: 6871687. DOI: 10.1002/hbm.20111. View

3.
Witkin J, Tzavara E, Nomikos G . A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol. 2005; 16(5-6):315-31. DOI: 10.1097/00008877-200509000-00005. View

4.
Dean B, Sundram S, Bradbury R, Scarr E, Copolov D . Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience. 2001; 103(1):9-15. DOI: 10.1016/s0306-4522(00)00552-2. View

5.
Li C, Huang C, Constable R, Sinha R . Imaging response inhibition in a stop-signal task: neural correlates independent of signal monitoring and post-response processing. J Neurosci. 2006; 26(1):186-92. PMC: 6674298. DOI: 10.1523/JNEUROSCI.3741-05.2006. View